Get the Stockscreener App
0.8484
4.43%
-0.0393
Pre-market:
.84
-0.0084
-0.99%
Standard Biotools Inc stock is traded at $0.8484, with a volume of 1.89M.
It is down -4.43% in the last 24 hours and down -13.85% over the past month.
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
See More
Previous Close:
$0.8877
Open:
$0.9
24h Volume:
1.89M
Relative Volume:
0.66
Market Cap:
$332.12M
Revenue:
$86.26M
Net Income/Loss:
$-50.08M
P/E Ratio:
-3.4643
EPS:
-0.2449
Net Cash Flow:
$-94.48M
1W Performance:
+5.63%
1M Performance:
-13.85%
6M Performance:
-43.81%
1Y Performance:
-19.20%
1-Day Range:
$0.8372
$0.90
1-Week Range:
$0.79
$0.9351
52-Week Range:
$0.79
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Name
Standard Biotools Inc
Sector
Industry
Phone
(650) 266-6000
Address
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
0.8484 | 332.12M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
88.67 | 154.45B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.94 | 118.05B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
80.38 | 103.20B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
46.76 | 69.50B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.28 | 49.68B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-13-25 | Downgrade | TD Cowen | Buy → Hold |
| Feb-27-25 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-16-24 | Initiated | TD Cowen | Buy |
| Apr-04-24 | Initiated | Jefferies | Buy |
| Jul-12-23 | Initiated | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Stock (LAB) Latest News
Are ROKU, PAYO, LAB, FOX Obtaining Fair Deals for their Shareholders? - TradingView
LAB Stock Alert: Halper Sadeh LLC is Investigating Whether Standard BioTools Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
Viking backs Standard BioTools (LAB) merger with Treeline Biosciences - Stock Titan
Casdin funds deepen tie to Standard BioTools (LAB) with 23.9% stake and Treeline merger support - Stock Titan
Company that shut down Peninsula HQ now swept up in reverse merger - The Business Journals
Crude Oil Gains Over 1%; Motorcar Parts Of America Shares Surge After Q4 Earnings - Sahm
Stealthy startup Treeline plans a reverse merger - BioPharma Dive
Standard BioTools to merge with Treeline in biotech transformation deal - The Pharma Letter
Standard BioTools Inc. (LAB) Discusses Merger and Strategic RationaleSlideshow (NASDAQ:LAB) 2026-06-08 - Seeking Alpha
Standard BioTools (LAB) Plunges Over 30%, Testing Critical Support at $0.76PCR Spike - newsline.com
Standard BioTools and Treeline Biosciences anno... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Standard BioTools and Treeline Biosciences Announce $900M Merger to Form Public Biopharma Company Focused on Oncology and Precision Medicines 12 - Minichart
Standard BioTools to Merge with Treeline Biosciences - TipRanks
Standard BioTools (NASDAQ: LAB) to merge with Treeline in $2.5B exchange‑ratio deal - Stock Titan
Standard BioTools to Merge With Treeline in All-Stock Deal Valuing Treeline at $2.5 Billion - TradingView
Treeline Biosciences, Standard BioTools (NASDAQ: LAB) plan all-stock merger - Stock Titan
Standard BioTools and Treeline Biosciences Agree to Merger, Creating Well-Funded Clinical-Stage Biopharma Company - citybiz
Standard BioTools, Treeline Biosciences to Merge in All-Stock Deal - marketscreener.com
Standard BioTools to merge with Treeline Biosciences By Investing.com - Investing.com Nigeria
Standard BioTools to merge with Treeline Biosciences - Investing.com
$900M cancer drug pipeline: Treeline, Standard BioTools to merge - Stock Titan
Standard BioTools Regains Compliance With Nasdaq's Minimum Bid Price Requirement - marketscreener.com
Standard BioTools and Treeline Biosciences Announce Merger Agreement - GlobeNewswire
Fenwick Represents Treeline Biosciences in Definitive Merger Agreement with Standard BioTools - fenwick.com
Standard BioTools Inc. 8-K Filing Details for June 5, 2026: Company Information, NASDAQ Listing, and Legal Disclosures – Minichart - Minichart
Standard BioTools Regains Nasdaq Minimum Bid Compliance Status - TipRanks
Standard BioTools regains Nasdaq bid-price compliance; matter closed - TradingView
Standard BioTools (NASDAQ: LAB) back in compliance with Nasdaq bid rule - Stock Titan
Standard BioTools Grants RSUs to Chief Business Officer - TipRanks
Standard BioTools (LAB) awards 500,000 RSUs to Chief Business Officer - Stock Titan
Standard BioTools Adopts New Executive Severance Protection Plans - TipRanks
Standard BioToolsapproves 2026 change of control and severance plan on May 21, 2026 - marketscreener.com
Standard BiotoolsApproves 2026 Change Of Control And Severance Plan On May 21, 2026 - TradingView
Standard BioTools CFO Alex Kim and CBO Sean Mackay enter 2026 Severance Plan; CEO Michael Egholm joins 2023 Plan - TradingView
Standard BioTools (LAB) sets new executive and CEO change-of-control severance terms - Stock Titan
Standard Biotools Live Share Prices and Trades. LAB.US Live Streaming Share Prices. - London South East
Standard BioTools shares hold over $1 as Nasdaq deadline nears - Bez Kabli
Standard BioTools (LAB) Hovers Near Support After Modest DeclineBlue Chip Entry Points - The Legal Advocate
Standard BioTools (LAB) Nears Support After Slight Decline Amid Cautious TradingValue Stock Ideas - The Legal Advocate
STANDARD BIOTOOLS (LAB) CFO has 18,871 shares withheld for RSU taxes - Stock Titan
Standard Biotools (LAB) SVP has 25,729 shares withheld for taxes - Stock Titan
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations - Stock Titan
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Fails to Lift Shares Amid Revenue UncertaintyProfit Announcement - Newser
DKSH : and Standard BioTools Announce Distribution Partnership to Expand Spatial Biology and Proteomics Solutions in Australia and New Zealand - marketscreener.com
Standard BioTools (LAB) Q1 2026 Earnings: $0.33 EPS Surges Past $-0.06 EstimatesStock Idea Hub - Newser
Standard BioTools (LAB) Q1 2026 Earnings Surprise: EPS $0.33, Up SignificantCrowd Consensus Signals - Newser
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player - AD HOC NEWS
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools - Stock Titan
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools - Stock Titan
Should You Sell Standard BioTools (LAB) After -1.52% Drop? 2026-05-15Collaborative Trading Signals - Newser
Standard Biotools Inc Stock (LAB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.35%
0.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):